faricimab-svoa (Vabysmo)
Jump to navigation
Jump to search
Indications
- treatment of:
- age-related macular degeneration
- macular edema
Pharmacokinetics
- expected to be catabolized like endogenous immunoglobulin
- appparent systemic 1/2 life of 7.5 days
Adverse effects
- risk of transient increases in intraocular pressure, endophthalmitis, & retinal detachment
- low risk of arterial thromboembolism
Mechanism of action
- IgG1-based dual specific antibody against VEGF-A & Ang-2
- suppresses endothelial proliferation, neovascularization, & vascular permeability
More general terms
References
- ↑ DrugBank Online https://go.drugbank.com/drugs/DB15303
- ↑ Hutton D Studies: Faricimab improved and maintained vision for patients with wet AMD, DME. Ophthalmology Times. 2022. Jan 24 https://www.ophthalmologytimes.com/view/studies-faricimab-improved-and-maintained-vision-for-patients-with-wet-amd-dme
- ↑ Sharma A, Kumar N, Parachuri N et al Faricimab phase 3 DME trial significance of personalized treatment intervals (PTI) regime for future DME trial. Eye 2021. Aug 15 https://www.nature.com/articles/s41433-021-01831-4
- ↑ Wikipedia: Faricimab https://en.wikipedia.org/wiki/Faricimab